Shares of Beam Therapeutics Inc. (NASDAQ: BEAM) were down in morning trading on Friday even as the biotechnology company announced that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold and cleared the Investigational New Drug (IND) application for BEAM-201.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
BEAM-201 is the company’s drug candidate for the treatment of acute lymphoblastic leukemia.
